small molecule

WEGOVY

SEMAGLUTIDE

Loss of exclusivityFebruary 2039latest FDA-listed patent expiry

CompanyNOVO NORDISK INC

Drug detail

Brand name	WEGOVY
Active ingredient	SEMAGLUTIDE
Strength	9MG
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	December 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12396953	February 2039	product
11833248	February 2039	product
10278923	May 2034	use U-4389
12239739	May 2034	use U-4388
11033499	June 2033	product
11382957	December 2031	product
9278123	December 2031	product
8129343	December 2031	substance, product
8536122	March 2026	substance, product

Regulatory exclusivity

Code	Expires
NP	December 2028
I-935	March 2027

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from NOVO NORDISK INC